Novavax's decision to distribute its Covid-19 vaccine through GPO agreements, including with Vizient, Inc., Premier, and Healthtrust Purchasing Group, could potentially increase its distribution and sales. This could lead to increased revenues and profitability, which would likely have a positive impact on its stock price.